Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 3/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10148299 | 0.91 | HRH3 (0.45) | HRH3FFAR4PTGS1PTGS2ACACB | |
| SCHEMBL10184293 | 0.85 | HRH3 (0.48) | HRH3FFAR4PTGS1PTGS2ACACB | |
| SCHEMBL10186399 | 0.84 | CRBN (0.41) | HRH3MAOBMAOAFFAR4PTGS1 | |
| SCHEMBL10148306 | 0.82 | SCN9A (0.41) | FFAR4ACACBSCN9A | |
| SCHEMBL3846215 | 0.81 | PTGS1 (0.59) | HRH3MAOBMAOAFFAR4PTGS1 | |
| SCHEMBL10148325 | 0.81 | ACACB (0.38) | FFAR4ACACB | |
| SCHEMBL10148307 | 0.80 | SMN1; SMN2 (0.49) | ACACBPARP10 | |
| SCHEMBL10186395 | 0.78 | NR1H4 (0.44) | HRH3 | |
| SCHEMBL10148311 | 0.77 | NPC1 (0.46) | HRH3MAOBMAOAPTGS1PTGS2 | |
| SCHEMBL12440598 | 0.77 | EPHX2 (0.42) | ACACBPARP10ACSL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | HRH3 2422/4885MAOB 2552/4885MAOA 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.